Literature DB >> 25860436

Clinical Muscle Testing Compared with Whole-Body Magnetic Resonance Imaging in Facio-scapulo-humeral Muscular Dystrophy.

J U Regula1, L Jestaedt2, F Jende3, A Bartsch2, H-M Meinck3, M-A Weber4,5.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the clinical usefulness of whole-body magnetic resonance imaging (MRI) in facio-scapulo-humeral muscular dystrophy (FSHD).
METHODS: In 20 patients with genetically proven FSHD1, we prospectively assessed muscular involvement and correlated the results of semi-quantitative manual muscle testing and other parameters such as disease duration, creatine kinase (CK) levels and repeat length of the D4Z4 locus with whole-body MRI.
RESULTS: Clinical muscle testing revealed the trapezius, pectoralis and infraspinatus as the most severely affected muscles in the shoulder, and the knee flexors and gluteus medius in the hip girdle. MRI revealed the trapezius and serratus anterior muscles in the shoulder, and the hamstrings and adductor muscles in the hip girdle, as the most severely affected muscle groups. Overall, degrees of fatty degeneration on MRI scans correlated significantly with clinical weakness. Moreover, we could detect clear affection of the trunk muscles. Corresponding to earlier reports, asymmetric involvement was frequent in both clinical examination and MRI scoring. Moreover, MRI revealed inhomogeneous muscle degeneration in a considerable proportion of both, muscles and patients. Both clinical and MRI scores significantly correlated to disease duration, but not to fragment size or CK levels.
CONCLUSION: Fatty degeneration in whole-body MRI correlates well to clinical muscle testing of the extremities but gives more information on deeper or trunk muscles. It shows structural changes in muscular disorders and may become an excellent tool for assessment of muscle involvement and follow-up studies.

Entities:  

Keywords:  Clinical muscle testing; FSHD; Muscle MRI

Mesh:

Year:  2015        PMID: 25860436     DOI: 10.1007/s00062-015-0386-y

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


  34 in total

1.  Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.

Authors:  David B Olsen; Peter Gideon; Tina Dysgaard Jeppesen; John Vissing
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

Review 2.  Facioscapulohumeral dystrophy.

Authors:  Shree Pandya; Wendy M King; Rabi Tawil
Journal:  Phys Ther       Date:  2007-11-06

3.  Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy.

Authors:  Hermien E Kan; Tom W J Scheenen; Marielle Wohlgemuth; Dennis W J Klomp; Ivonne van Loosbroek-Wagenmans; George W Padberg; Arend Heerschap
Journal:  Neuromuscul Disord       Date:  2009-03-28       Impact factor: 4.296

Review 4.  Facioscapulohumeral muscular dystrophy.

Authors:  Sabrina Sacconi; Leonardo Salviati; Claude Desnuelle
Journal:  Biochim Biophys Acta       Date:  2014-05-29

5.  Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.

Authors:  Berit Jordan; Katharina Eger; Sabrina Koesling; Stephan Zierz
Journal:  J Neurol       Date:  2010-12-17       Impact factor: 4.849

6.  Whole-body high-field MRI shows no skeletal muscle degeneration in young patients with recessive myotonia congenita.

Authors:  C Kornblum; G G Lutterbey; B Czermin; J Reimann; J-C von Kleist-Retzow; K Jurkat-Rott; M P Wattjes
Journal:  Acta Neurol Scand       Date:  2009-12-28       Impact factor: 3.209

7.  Pattern of skeletal muscle involvement in primary dysferlinopathies: a whole-body 3.0-T magnetic resonance imaging study.

Authors:  K Kesper; C Kornblum; J Reimann; G Lutterbey; R Schröder; M P Wattjes
Journal:  Acta Neurol Scand       Date:  2008-12-22       Impact factor: 3.209

Review 8.  Neuromuscular imaging in inherited muscle diseases.

Authors:  Mike P Wattjes; Rudolf A Kley; Dirk Fischer
Journal:  Eur Radiol       Date:  2010-04-27       Impact factor: 5.315

9.  Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration.

Authors:  Barbara H Janssen; Nicoline B M Voet; Christine I Nabuurs; Hermien E Kan; Jacky W J de Rooy; Alexander C Geurts; George W Padberg; Baziel G M van Engelen; Arend Heerschap
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

10.  Upper girdle imaging in facioscapulohumeral muscular dystrophy.

Authors:  Giorgio Tasca; Mauro Monforte; Elisabetta Iannaccone; Francesco Laschena; Pierfrancesco Ottaviani; Emanuele Leoncini; Stefania Boccia; Giuliana Galluzzi; Marco Pelliccioni; Marcella Masciullo; Roberto Frusciante; Eugenio Mercuri; Enzo Ricci
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more
  5 in total

Review 1.  Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review.

Authors:  Doris G Leung
Journal:  J Neurol       Date:  2016-11-25       Impact factor: 4.849

2.  MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.

Authors:  Grete Andersen; Julia R Dahlqvist; Christoffer R Vissing; Karen Heje; Carsten Thomsen; John Vissing
Journal:  J Neurol       Date:  2016-12-20       Impact factor: 4.849

3.  Adding quantitative muscle MRI to the FSHD clinical trial toolbox.

Authors:  Karlien Mul; Sanne C C Vincenten; Nicol C Voermans; Richard J L F Lemmers; Patrick J van der Vliet; Silvère M van der Maarel; George W Padberg; Corinne G C Horlings; Baziel G M van Engelen
Journal:  Neurology       Date:  2017-10-13       Impact factor: 9.910

4.  Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative study.

Authors:  Farzad Fatehi; Emmanuelle Salort-Campana; Arnaud Le Troter; Emilie Lareau-Trudel; Mark Bydder; Alexandre Fouré; Maxime Guye; David Bendahan; Shahram Attarian
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

Review 5.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.